The US Peptide Therapeutics Market has been projected at $52.6 billion in 2025 by Holt Law's market report, reflecting the combined scope of GLP-1 and non-GLP-1 peptide pipeline commercialisation pressure
Related: This Common GLP-1 Dosing Mistake Can Backfire Fast, Doctors Warn "According to the Food and Drug Administration, semaglutide and tirzepatide are no longer in shortage as of February 21, 2025
Many insurance plans require documented diet and exercise attempts, require prior authorization, or limit coverage to patients with specific comorbidities
NAD+ (Nicotinamide Adenine Dinucleotide) supports cellular energy production, enhances metabolic functions, and may contribute to overall well-being
A 10mg vial gives you roughly a month at the same dose, which aligns better with the 28-day stability window after reconstitution